Visualization firms invest in TeraRecon
Fujifilm and Pentax have invested millions of dollars in TeraRecon as part of strategic alliance agreements that call for the image processing pioneer to collaborate on new product and technology development. Fujifilm of Tokyo, Japan, finalized its deal
Fujifilm and Pentax have invested millions of dollars in TeraRecon as part of strategic alliance agreements that call for the image processing pioneer to collaborate on new product and technology development. Fujifilm of Tokyo, Japan, finalized its deal in March; Pentax signed its agreement in May. Both agreements were announced earlier this month. Fujifilm paid $4.95 million to acquire 300,000 shares of newly issued series G preferred stock, representing a 1.92% equity stake in TeraRecon. Under the terms of the alliance, TeraRecon will apply its signal and image processing technologies to new product and technology development at Fuji. Pentax paid $5.67 million to acquire 341,000 shares of newly issued series G preferred stock, representing 2.18% of issued equity. In return, Pentax has the right to include TeraRecon technology in products such as those involving optical endoscopic imaging and consumer electronics digital camera applications.
Large Study Affirms Safety of Ultrasound Enhancing Agents for Echocardiography
May 16th 2025Those receiving ultrasound enhancing agents (UEAs) for transthoracic or stress echocardiography had lower odds of all-cause death in comparison to patients who did not have UEAs, according to a nationwide study involving 11.4 million patients.
BrightHeart Garners Third FDA Clearance for AI-Powered Assessments of Fetal Heart Ultrasound
May 14th 2025The latest FDA 510(k) clearance is for B-Right Views, an AI-enabled device, which provides automated detection of required views necessary for second- and third-trimester fetal heart ultrasound exams.
